Is Sionna Therapeutics, Inc. (SION) a Buy, Sell, or Hold?
Sionna Therapeutics, Inc.
NASDAQ:SION
$42.59 USD
-$1.36 (-3.09%)
- Volume
- 288.61K
- Average Volume
- 446.85K
- Market Capitalization
- $1.92B
- P/E Ratio
- -22.07
- Dividend Yield
- 0.00%
- Price Target
- $52.50
- Year High
- $48.45
- Year Low
- $16.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $22.60
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael Cloonan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SION |
| CUSIP | 829401108 |
| CIK | 0002036042 |
| Web | https://www.sionnatx.com |
| Phone | 617 819 2020 |
| Currency | USD |
| Employees | 59 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 22.60 |
| Quick Ratio | 22.60 |
| Cash Ratio | 6.48 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.61 |
| Price / Cash Flow | -26.66 |
| Price / Book | 6.64 |
Price Target and Rating
| Average Stock Price Forecast | $52.50 |
| High Stock Price Forecast | $55.00 |
| Low Stock Price Forecast | $50.00 |
| Forecast Upside/Downside | -18.88% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.88 |
| Trailing P/E Ratio | -22.07 |
| PEG Ratio | 0.87 |
| P/E Growth | 0.87 |
| Net Income | $-75.27M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -27.31% |
| Return on Assets | -28.05% |
Financials Score
| AltmanZ Score | 69.38 |
| Piotroski Score | 1.00 |
| Working Capital | 211.18M |
| Total Assets | 305.04M |
| Ebit | -82.39M |
| Market Cap | 1.98B |
| Total Liabilities | 16.83M |
Poll Results
About Sionna Therapeutics, Inc. (NASDAQ:SION) Stock
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator. ...
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment
2026-06-30 07:12:54
Sionna Therapeutics targets cystic fibrosis with a novel NBD1 stabilization mechanism, aiming to enhance CFTR function beyond current standards. SION-719 as an add-on to Trikafta and SION-451 dual combinations both approach pivotal clinical readouts in summer 2026, offering dual strategic paths. Sionna's $289.9M cash runway extends to 2028, supporting critical proof-of-concept milestones without near-term financing risk.
2026-06-10 13:52:13
Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
2026-05-27 08:00:00
WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-13 08:00:00
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.
Sionna Therapeutics Reports First Quarter 2026 Financial Results
2026-05-12 07:00:00
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026 Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
2026-04-27 07:00:00
Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock
2026-04-19 05:23:10
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Orbimed Advisors Llc sold 47,814 shares of the company's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the sale, the director directly owned 3,482,888 shares of
Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock
2026-04-19 05:23:09
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Peter Thompson sold 47,814 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the transaction, the director owned 3,482,888 shares in
Frequently Asked Questions
-
What is the current Sionna Therapeutics, Inc. (SION) stock price?
-
Sionna Therapeutics, Inc.(NASDAQ:SION) stock price is $42.59 in the last trading session. During the trading session, SION stock reached the peak price of $48.445 while $16.38 was the lowest point it dropped to. The percentage change in SION stock occurred in the recent session was --3.09% while the dollar amount for the price change in SION stock was -$-1.36.
-
SION's industry and sector of operation?
-
The NASDAQ listed SION is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SION?
-
Charlotte McKee | Chief Medical Officer
Greg Hurlbut | Co-Founder & Senior Vice President of Discovery Research
Mark Munson | Co-founder & Senior Vice President of Medicinal Chemistry
Andy Chu | Vice President of Information & Technology
Michael Cloonan | President, Chief Executive Officer & Director -
How many employees does SION have?
-
Number of SION employees currently stands at 59. SION operates from 21 Hickory Drive Suite 500, Waltham, MA 02451, US.
-
Link for SION official website?
-
Official Website of SION is: https://www.sionnatx.com
-
How do I contact SION?
-
SION could be contacted at phone #617 819 2020 and can also be accessed through its website. SION operates from 21 Hickory Drive Suite 500, Waltham, MA 02451, US.
-
How many shares of SION are traded daily?
-
The average number of SION shares traded daily for last 3 months was 446.85K.
-
What is the market cap of SION currently?
-
The market value of SION currently stands at $1.92B with its latest stock price at $42.59